Psychemedics Corp Files 8-K Report

TL;DR

Psychemedics Corp filed a routine 8-K on Dec 10, 2024. No major news yet.

AI Summary

On December 10, 2024, Psychemedics Corporation filed an 8-K report. The filing indicates that the company is a medical laboratory services provider incorporated in Delaware with its principal executive offices located in Dallas, Texas. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing serves as a notification to the SEC and investors about the company's status and any material events. Investors can use this to stay informed about corporate actions.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that would indicate significant risk.

Key Numbers

• 001-13738 — SEC File Number (Identifies the company's filing history with the SEC.)
• 58-1701987 — I.R.S. Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• PSYCHEMEDICS CORP (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Dallas, Texas (location) — Address of Principal Executive Offices
• December 10, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.005 — nge on which registered Common Stock. $0.005 par value per share PMD The Nasdaq
• $2.35 — y's common stock at a purchase price of $2.35 per share based on available estimates
• $500,000 — sulted from the reverse stock split and $500,000 for working capital and general corpora

Filing Documents

• f8k_121024.htm (8-K) — 20KB
• 0001171843-24-006863.txt ( ) — 191KB
• pmd-20241210.xsd (EX-101.SCH) — 3KB
• pmd-20241210_lab.xml (EX-101.LAB) — 33KB
• pmd-20241210_pre.xml (EX-101.PRE) — 24KB
• f8k_121024_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. On December 3, 2024, Psychemedics Corporation (the "Company") closed the transactions contemplated by the previously announced stock purchase agreement, by and among the Company, 3K Limited Partnership, a Delaware limited partnership ("3K"), Peter H. Kamin, the Peter H. Kamin Revocable Trust dated February 2003, the Peter H. Kamin Childrens Trust dated March 1997, the Peter H. Kamin GST Trust and the Peter H. Kamin Family Foundation, pursuant to which 3K purchased 1,409,712 shares of the Company's common stock at a purchase price of $2.35 per share based on available estimates of the funds required for the Company to purchase all of the fractional share interests that resulted from the Company's previously announced reverse stock split of its common stock, and thereafter, the Company repurchased on December 10, 2024 320,708 of such shares of common stock from 3K at the same price once confirmation of the total required funds was available from the Company's transfer agent. 3K provided the Company sufficient funds to purchase all of the fractional share interests that resulted from the reverse stock split and $500,000 for working capital and general corporate purposes.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PSYCHEMEDICS CORPORATION Date: December 10, 2024 By: /s/ Brian Hullinger Name: Brian Hullinger Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR